LSL Pharma Group Inc. (TSXV:LSL)

Canada · Delayed Price · Currency is CAD

0.3200

-0.0100 (-3.03%)

At close: Aug 28, 2026

LSL Pharma Group Financials Overview

Financials in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	41.83	28.74	17.75	10.03	8.21	8.77
Revenue Growth	80.01%	61.96%	76.98%	22.08%	-6.35%	-12.70%
Gross Profit	5.17	6.82	5.35	1.65	-2.17	1.88
Operating Income	-4.26	-0.59	0.41	-4.12	-6.76	-0.71
Net Income	-7.34	-2.82	3.32	-8.47	-8.06	-1.78
Earnings Per Share	-0.06	-0.02	0.03	-0.11	-0.12	-0.03
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
CMO	27.9	25.5	10.54	4.87
Eye-care Division	4.3	3.25	7.21	5.16
Total	41.83	28.74	17.75	10.03

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	0.97	0.55	0.3	0.01	0	0.74
Total Debt	50.59	38.35	21.64	16.27	15.03	12.74
Net Cash (Debt)	-49.63	-37.8	-21.34	-16.26	-15.03	-12
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-0.40	-0.32	-0.20	-0.20	-0.23	-0.20

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-5.86	-2.45	-1.65	-7.07	-3.16	-1.08
Capital Expenditures	-1.86	-2.02	-1.6	-0.66	-1	-0.91
Free Cash Flow	-7.71	-4.46	-3.25	-7.73	-4.16	-2
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	12.37%	23.74%	30.13%	16.40%	-26.44%	21.47%
Operating Margin	-10.19%	-2.05%	2.29%	-41.05%	-82.26%	-8.07%
Pretax Margin	-17.69%	-10.04%	18.97%	-84.48%	-98.15%	-18.58%
Profit Margin	-17.54%	-9.81%	18.69%	-84.48%	-98.15%	-20.26%
FCF Margin	-18.44%	-15.53%	-18.31%	-77.04%	-50.66%	-22.80%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	-	-	14.28	-	-	-
PS Ratio	0.97	1.48	2.67	3.99	-	-